← All candidates
140 insider filings on record.
Gilbert Ray Cisneros, Jr.Small Business · Armed Servicestraded 29 May · filed 8 Jun · selfBuy$1K–$15Kself29 May110d ago8 Jun100d agoGilbert Ray Cisneros, Jr.Small Business · Armed Servicestraded 3 Mar · filed 7 Apr · selfBuy$1K–$15Kself3 Mar197d ago7 Apr162d ago140 filings on record.
ARQTArcutis Biotherapeutics, Inc.
NasdaqGS · Healthcare · $2.96B
$23.51
-3.13% · Sep 15
140 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 68 sells◆ 2 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$2.96B
Float
93.8M
75% public
Short % float
Pro
Price / profit
112.0
Price / future profit
17.3
Price / sales
6.4
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Heron Patrick J
Bought $34.6K on Jun 13 — 2,646 sh @ $13.08, held indirect, 9.6% of their stake.
3 of 3 positions beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
Congress
▸ Disclosures lag trades by 30–45 days.
3 disclosures12 mo
MemberTypeAmountOwnerTradedFiled
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
135 more transactions on Pro →Context
Wall St
$34.63 avg target
+47.3% vs today · 8 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$0.09 act−$0.03
Q4 '25$0.13 act+$0.04
Q3 '25$0.06 act+$0.15
Q2 '25−$0.13 act+$0.03
Coverage
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy?Simply Wall St. · 06-12Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive StatusMarketBeat · 06-10Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE ExpansionSimply Wall St. · 05-09
The file stays open
140 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice